Controlled Trial of Valacyclovir in Infectious Mononucleosis

Completed · Phase 1/Phase 2

Conditions studied: Infectious Mononucleosis

In brief

The hypothesis is that an antiviral drug (valacyclovir) will reduce the amount of Epstein-Barr virus (EBV) in the mouths of university students with infectious mononucleosis (mono) while being a safe drug. Because EBV is the cause of mono, it is expected that reduction of the amount of virus could result in faster recovery from the disease.

Key facts

Study ID

NCT00274404

Run by

University of Minnesota

People needed

20

Starts

2004-02-01

Expected to finish

2005-09-01

Last updated by the study team

2011-10-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of infectious mononucleosis with onset no more the 7 days before enrollment; willingness to sign informed consent
• Willingness to provide blood and oral washing samples at regular intervals
• Females must have a negative urine pregnancy test and agree to use effective contraception (barrier or hormonal) for the first 30 days of the study if assigned to valacyclovir
• Corticosteroids are permitted only if prescribed by the subject's primary physisican for treatment of this acute disease

You may not qualify if…

• Previous history of mono
• Pregnant or breast feeding
• End-stage renal or liver disease
• Immunosuppressed due to underlying medical disease and/or immunomodulating medications prior to enrollment
• Onset of present illness >7 days ago

Where it is running

• University of Minnesota Clinical Virology Clinic — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.